Roche hands over another batch of positive PhIII data on its new flu drug, looking for an early-winter launch
Roche has taken another big stride toward gaining approval for its new flu therapy — eyeing a market launch just as winter is set to get serious.
We don’t have any data, but their second Phase III trial needed for a US OK has come through positive on the primary as well as several secondary endpoints. And the results come on top of its initial success, which laid the foundation for its regulatory package at the agency, slated to deliver an accelerated decision by Christmas Eve.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.